Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
UPDATE: RBC Capital Issues Positive Comments on Akebia Therapeutics (AKBA), Believes Shares Could Trade Up $5 to $8 on Data
May 5, 2020 9:24 AM EDT(Updated - May 5, 2020 9:25 AM EDT)
(expanding comment)
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Akebia Therapeutics (NASDAQ: AKBA)
The analyst comments "This morning AKBA announced positive topline results from the ph3 INNO2VATE studies (n=3,902) of vadadustat... More
Akebia Therapeutics (AKBA) Tops Q1 EPS by 15c
May 5, 2020 7:43 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More